The Mirum Pharmaceuticals IBAT bile acid transporter inhibitor, maralixibat , has a long history, having been first patented by scientists at Searle in 1994 and published by the time Searle became part of Pharmacia in 2005 . It was finally approved in Sep. 2021 for treatment of cholestatic pruritis in patients with Alagille Syndrome, and is [...]
< 1 minute read
Dec. 10, 2021
Maralixibat: An Oral Gut-Restricted Bile Acid Transporter Inhibitor
maralixibat
oral gut-restricted bile acid transporter inh. approved for cholestatic pruritis in Sep. 2021 repurposed (first patented in 1994) The Lancet Mirum / Pfizer / Pharmacia / Searle
Loading...
